Sign In

Arnon Horev

Co-Founder @ QuantHealth, Health-Tech Entrepreneur

Arnon Horev is a dedicated professional with a strong passion for introducing innovative healthcare technologies to the global market through collaborative team efforts.

Arnon Horev's expertise lies in leading sales and marketing teams within the healthcare sector, playing crucial roles in the development and successful market adoption of cutting-edge solutions.

Currently, he is the Co-Founder and Chief Business Officer at QuantHealth, a pioneering company that offers clinical simulation services to pharma and biotech firms, aiding in optimizing trial designs and minimizing trial failures efficiently.

Arnon Horev's educational background includes a focus on healthcare and business administration, with studies in CRA, ICH-GCP, FDA Regulations, an MBA with a concentration in Health Sector Management from Duke University, and a B.Sc. in Life Sciences from Ben-Gurion University of the Negev.

With a rich professional history, Arnon Horev has held key positions such as Chief Business Officer at Nucleai, Director of Product Marketing at Nucleix Ltd., Director of Marketing & OEM Activities at EarlySense, and Strategic Accounts Manager at EarlySense.

Additionally, he has valuable experience as a Medical Device Consultant, VP of Sales & Marketing, Director of Marketing, and a Brand Manager in prominent companies like BioElectronics Corporation.

Arnon Horev's early career involved roles such as an MBA Summer Intern at Bristol-Myers Squibb and a Product Specialist/Medical Sales Representative at Janssen Pharmaceuticals, part of Johnson and Johnson.

His relentless drive to innovate in healthcare and his track record of success in various leadership positions highlight Arnon Horev's commitment to advancing the industry.

Arnon Horev's dedication to teamwork and his ability to lead organizations to successful market outcomes underscore his reputation as a seasoned professional in the healthcare technology sector.

Highlights

Jan 8 · linkedin

We are thrilled to announce that Accenture, a global leader in connecting technology to clinical development, has joined our journey as a strategic investor. With their support, we have extended our A round to $17M. We are grateful to Tom Lounibos, Frances Taheri, and Dr. Petra Jantzer for believing in our mission and for their trust in our team.

Read more about our exciting news here: https://lnkd.in/dXsUq8aX

Oct 26 · linkedin

About 2.5 years ago, I co-founded QuantHealth together with Orr Inbar and I couldn't wish for a better partner. We had a clear vision of how we want to help and solve the $45B/year problem of failed clinical trials through the use of a completely novel AI approach. This is extremely meaningful as it can allow patients to benefit from more and better treatments, that are coming faster to the world and with significantly lower cost. Back then F2 Venture Capital were the first to invest and believe in us.

In the last 2.5 years we worked non-stop on bringing this vision into a reality, where many of our super-talented teammates joined us as pioneers in this unique adventure - Eran Barash, Omri Matalon (PhD), Vadim Livshits, Hila Yanay Brot, Julien Benchetrit, Rotem Marco Ben-David, Marina Goldman, Amichai Perlman, Amina Alaskarov, Matthew Kudelin, Hodaya Beer and Denise Rosegg. With this incredible team we made a huge progress where we could show the world that what we imagined can be achieved, and already brought value to various pharma partners around the world.

Today, we announced additional partners that not only believe in what we do, but also already put extraordinary value into it - Eran Lerer (Shoni Top), Ittai Harel (Pitango), Marta-Gaia Zanchi (Nina Capital), Yonatan Brender (ATOORO FUND), Brigham Hyde (through Renegade) and Dana Callow (Boston Millennia Partners). We already understand that we are extremely lucky to have such investors. These partners will help us progress to the next level.

Arnon Horev
Add to my network

Location

Israel